HC Wainwright Research Analysts Lower Earnings Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) – Stock analysts at HC Wainwright reduced their Q2 2024 earnings per share estimates for shares of Kiora Pharmaceuticals in a research note issued on Monday, May 20th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.09) per share for the quarter, down from their previous estimate of ($0.08). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $0.11 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.08) EPS and FY2024 earnings at $0.15 EPS.

Kiora Pharmaceuticals Trading Down 1.3 %

NASDAQ KPRX opened at $0.53 on Wednesday. The firm’s 50 day moving average price is $0.56 and its two-hundred day moving average price is $0.58. Kiora Pharmaceuticals has a twelve month low of $0.45 and a twelve month high of $2.24.

Institutional Investors Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. purchased a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals makes up 1.5% of Rosalind Advisors Inc.’s holdings, making the stock its 22nd biggest holding. Rosalind Advisors Inc. owned about 8.76% of Kiora Pharmaceuticals as of its most recent filing with the SEC. Institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.